Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D F Archer

Showing results (81-90 of 115) with videos related to

Pageof 12
Sort By:
American Journal of Obstetrics and Gynecology|July 15, 1982
Bromocriptine treatment of women with suspected pituitary prolactin-secreting microadenomasD F Archer, D R Lattanzi, E E Moore, et al.
Climacteric : the Journal of the International Menopause Society|February 29, 2020
A pilot study: estradiol/progesterone effect on cervico-vaginal cytokines in premenopause and postmenopauseI Sriprasert, T Pakrashi, A Shah, et al.
Climacteric : the Journal of the International Menopause Society|September 7, 2020
Uterine bleeding with hormone therapies in menopausal women: a systematic reviewJ H Pickar, D F Archer, S R Goldstein, et al.
Contraception|August 1, 1997
A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopyC K Mauck, J M Baker, S P Barr, et al.
Contraception|August 1, 1997
A phase I comparative study of three contraceptive vaginal films containing nonoxynol-9. Postcoital testing and colposcopyC K Mauck, J M Baker, S P Barr, et al.
Fertility and Sterility|December 1, 1996
Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implantsE G Raymond, M Singh, D F Archer, et al.
Obstetrics and Gynecology|November 1, 1983
Etiology of recurrent pregnancy losses and outcome of subsequent pregnanciesJ H Harger, D F Archer, S G Marchese, et al.
Pharmaceutical Research|March 1, 1993
Tissue response to bioerodible, subcutaneous drug implants: a possible determinant of drug absorption kineticsF D Anderson, D F Archer, S M Harman, et al.
Contraception|August 1, 1997
An evaluation of the amount of nonoxynol-9 remaining in the vagina up to 4 h after insertion of a vaginal contraceptive film (VCF) containing 70 mg nonoxynol-9C K Mauck, S Allen, J M Baker, et al.
Obstetrics and Gynecology|August 29, 2000
Norethindrone acetate and estradiol-induced endometrial hyperplasiaR J Kurman, J C Félix, D F Archer, et al.
Pageof 12

Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
American Journal of Obstetrics and Gynecology|July 15, 1982
Bromocriptine treatment of women with suspected pituitary prolactin-secreting microadenomasD F Archer, D R Lattanzi, E E Moore, et al.
Climacteric : the Journal of the International Menopause Society|February 29, 2020
A pilot study: estradiol/progesterone effect on cervico-vaginal cytokines in premenopause and postmenopauseI Sriprasert, T Pakrashi, A Shah, et al.
Climacteric : the Journal of the International Menopause Society|September 7, 2020
Uterine bleeding with hormone therapies in menopausal women: a systematic reviewJ H Pickar, D F Archer, S R Goldstein, et al.
Contraception|August 1, 1997
A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopyC K Mauck, J M Baker, S P Barr, et al.
Contraception|August 1, 1997
A phase I comparative study of three contraceptive vaginal films containing nonoxynol-9. Postcoital testing and colposcopyC K Mauck, J M Baker, S P Barr, et al.
Fertility and Sterility|December 1, 1996
Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implantsE G Raymond, M Singh, D F Archer, et al.
Obstetrics and Gynecology|November 1, 1983
Etiology of recurrent pregnancy losses and outcome of subsequent pregnanciesJ H Harger, D F Archer, S G Marchese, et al.
Pharmaceutical Research|March 1, 1993
Tissue response to bioerodible, subcutaneous drug implants: a possible determinant of drug absorption kineticsF D Anderson, D F Archer, S M Harman, et al.
Contraception|August 1, 1997
An evaluation of the amount of nonoxynol-9 remaining in the vagina up to 4 h after insertion of a vaginal contraceptive film (VCF) containing 70 mg nonoxynol-9C K Mauck, S Allen, J M Baker, et al.
Obstetrics and Gynecology|August 29, 2000
Norethindrone acetate and estradiol-induced endometrial hyperplasiaR J Kurman, J C Félix, D F Archer, et al.
Pageof 12